Stock market today: S&P 500 hits fresh record close on stronger economic growth
LONDON - Shield Therapeutics (LON:STXS) plc (LSE:STX) reported Thursday that its total revenues grew 80% to $21.4 million in the first half of 2025 compared to the same period last year, driven by increased sales of its iron deficiency treatment ACCRUFeR.
The pharmaceutical company sold approximately 84,000 ACCRUFeR prescriptions during the period, representing a 30% increase from the first half of 2024. The average net selling price rose approximately 40% to $214 per prescription.
ACCRUFeR revenue reached $19.2 million, up 80% from $11 million in the comparable period last year. The company also generated $2.2 million in milestone payments and royalties from global partners in Europe, Canada and Japan, doubling the $1.1 million recorded in the first half of 2024.
Shield’s loss narrowed to $9.5 million from $15.5 million a year earlier, which the company attributed to higher revenues and streamlined business expenditures.
Cash and cash equivalents stood at $10.8 million as of June 30, up from $6.5 million at the end of December 2024, bolstered by $10 million in gross proceeds from equity funding and milestone payments from partners.
The company expanded its global presence with several partnership developments. ACCRUFeR launched in Canada in March through partner Kye Pharmaceuticals. In April, Shield entered an exclusive license agreement with VITAL-NET for development and commercialization in Japan, receiving an initial payment of approximately $665,000.
In China, partner ASK Pharma completed a Phase 3 study in adult patients with inflammatory bowel disease and iron deficiency anemia, with a new drug application expected to be filed later this year.
Shield also submitted regulatory filings to the European Medicines Agency and U.S. Food and Drug Administration for pediatric use of ACCRUFeR following positive clinical trial results.
According to the company’s press release statement, Shield remains on track to achieve positive cash flow by the end of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.